128 related articles for article (PubMed ID: 32974675)
21. Beneficial effect of hydroxychloroquine on cutaneous vasculitis in a Japanese patient with systemic lupus erythematosus.
Kibune N; Shimomura Y; Hasegawa A; Saeki T; Umemori Y; Abe R
J Dermatol; 2017 Apr; 44(4):e52-e53. PubMed ID: 27569899
[No Abstract] [Full Text] [Related]
22. Coexistence of Mixed Connective Tissue Disease and Familial Mediterranean Fever in a Japanese Patient.
Fujita Y; Asano T; Sato S; Furuya MY; Temmoku J; Matsuoka N; Kobayashi H; Watanabe H; Suzuki E; Koga T; Endo Y; Kawakami A; Migita K
Intern Med; 2019 Aug; 58(15):2235-2240. PubMed ID: 30996171
[TBL] [Abstract][Full Text] [Related]
23. Comment on: Coexistence of systemic lupus erythematosus and familial Mediterranean fever in a pediatric patient.
Kelesoglu FM; Saracoglu B; Ciftkaya A; Durmus RB; Kaya S; Ozer S; Makar CC; Yilmaz Y; Acar A; Omeroglu R
Lupus; 2016 Dec; 25(14):1623-1624. PubMed ID: 27013664
[No Abstract] [Full Text] [Related]
24. Familial Mediterranean FeVer gene (MEFV) mutations as a modifier of systemic lupus erythematosus.
Shinar Y; Kosach E; Langevitz P; Zandman-Goddard G; Pauzner R; Rabinovich E; Livneh A; Lidar M
Lupus; 2012 Aug; 21(9):993-8. PubMed ID: 22532615
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of familial Mediterranean fever and Sjögren's syndrome in a Japanese patient.
Tanaka M; Migita K; Miyashita T; Maeda Y; Nakamura M; Komori A; Ishibashi H; Eguchi K; Kikuchi M; Hirayama K; Yasunami M
Clin Exp Rheumatol; 2007; 25(5):792. PubMed ID: 18078637
[No Abstract] [Full Text] [Related]
27. Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus.
Wu CY; Tan M; Huang JY; Chiou JY; Wei JC
Ann Rheum Dis; 2022 May; 81(5):e75. PubMed ID: 32434824
[No Abstract] [Full Text] [Related]
28. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
Yokogawa N; Kato Y; Sugii S; Inada S
Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of familial Mediterranean fever and rheumatoid arthritis.
Migita K; Abiru S; Sasaki O; Miyashita T; Izumi Y; Nishino A; Jiuchi Y; Kawakami A; Yasunami M
Mod Rheumatol; 2014 Jan; 24(1):212-6. PubMed ID: 24261781
[TBL] [Abstract][Full Text] [Related]
30. Familial Mediterranean Fever Is Important in the Differential Diagnosis of Recurrent Aseptic Meningitis in Japan.
Hosoi T; Ishii K; Tozaka N; Kishida D; Sekijima Y; Tamaoka A
Intern Med; 2020 Jan; 59(1):125-128. PubMed ID: 31511485
[TBL] [Abstract][Full Text] [Related]
31. A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus.
Shindo E; Shikano K; Kawazoe M; Yamamoto T; Kusunoki N; Hashimoto Y; Nanki T
Lupus; 2019 Jul; 28(8):1017-1020. PubMed ID: 31166865
[TBL] [Abstract][Full Text] [Related]
32. Coexistence of polymyositis and familial Mediterranean fever.
Eguchi M; Miyashita T; Shirouzu H; Sato S; Izumi Y; Takeoka A; Ohno T; Sumiyoshi R; Nishino A; Jiuchi Y; Nonaka F; Eguchi K; Kawakami A; Migita K
Mod Rheumatol; 2013 Mar; 23(2):374-8. PubMed ID: 22534884
[TBL] [Abstract][Full Text] [Related]
33. Acquired Brown's syndrome in systemic lupus erythematosus: another ocular manifestation.
McGalliard J; Bell AL
Clin Rheumatol; 1990 Sep; 9(3):399-400. PubMed ID: 2261741
[TBL] [Abstract][Full Text] [Related]
34. The use of hydroxychloroquine in lupus pregnancy: the British experience.
Khamashta MA; Buchanan NM; Hughes GR
Lupus; 1996 Jun; 5 Suppl 1():S65-6. PubMed ID: 8803914
[TBL] [Abstract][Full Text] [Related]
35. [Periodic fever and etiocholanolone fever in chronic rheumatic diseases. Clinical case histories].
Schilling F; Oertel GW; Treiber L
Z Rheumaforsch; 1969; 28(3):117-25. PubMed ID: 5804797
[No Abstract] [Full Text] [Related]
36. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
37. Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al.
Costedoat-Chalumeau N; Amoura Z; Marra D; Piette JC
Arthritis Rheum; 2008 Jan; 59(1):153; author reply 153-4. PubMed ID: 18163410
[No Abstract] [Full Text] [Related]
38. Hydroxychloroquine in systemic lupus erythematosus.
Disla E; Brar H; Taranta A
N Engl J Med; 1991 Oct; 325(14):1046. PubMed ID: 1886629
[No Abstract] [Full Text] [Related]
39. Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu
Fanouriakis A; Bertsias G; Boumpas DT
Ann Rheum Dis; 2022 May; 81(5):e76. PubMed ID: 32434817
[No Abstract] [Full Text] [Related]
40. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
Kishi C; Motegi SI; Yasuda M; Ishikawa O
J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
